GSK: Result Summaries: Compounds > abacavir/lamivudine/zidovudine

Home > Result Summaries: Compounds > abacavir/lamivudine/zidovudine

Result Summaries: abacavir/lamivudine/zidovudine

Result Summaries for abacavir/lamivudine/zidovudine
GSK Study ID	Phase	Title
112877_5	N/A	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration (5 citation(s))
112878_5	N/A	Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus (0 citation(s))
112879_2	N/A	Incidence of abacavir hypersensitivity reactions in EuroSIDA (1 citation(s))
112885_3	N/A	Antiretroviral Pregnancy Registry (APR)-Risk of birth defects associated with exposure to GSK HIV drugs during pregnancy (1 citation(s))
112887_3	N/A	Studies using DAD - Effects of different interventions to improve ART-associated dyslipidemia (1 citation(s))
112889_1	N/A	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies (0 citation(s))
113039_3	N/A	Studies using DAD - Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? (1 citation(s))
113156_3	N/A	Studies using the VA - Studies done under the Oversight Committee for the Evaluation of the metabolic complications of HAART (2 citation(s))
113329_3	N/A	Lactic acid levels in children pre- and perinatally treated with antiretrovirals to prevent HIV transmission (Giaquinto; Hyperlactatemia in infants with in utero exposure to ZDV/3TC ) (2 citation(s))
113660	N/	TZV Epidemiology Program of HSR and Rechallenge HSR: VA (1 citation(s))
113671	N/	TZV Epidemiology Program of HSR and Rechallenge HSR: UHC (1 citation(s))
113761	N/	TZV Epidemiology Program of HSR and Rechallenge HSR: HIV Insight (1 citation(s))
113762	N/	TZV Epidemiology Program of HSR and Rechallenge HSR: CHORUS (1 citation(s))
AZL10001	Phase 1	An Evaluation of the Bioequivalence of a Combined Formulated Tablet (300/150/300mg abacavir/lamivudine/zidovudine) Compared to ZIAGEN (abacavir) 300mg tablet, EPIVIR (lamivudine) 150mg tablet, and RETROVIR (zidovudine) 300mg tablet Administered Concurrently and the Effect of Food on Absorption i ... (1 citation(s))
AZL10002	Phase 1	An Evaluation of the Steady-State Pharmacokinetics of abacavir, lamivudine, and zidovudine following administration of a Combined Formulated Tablet (300/150/300mg abacavir/lamivudine/zidovudine) versus ZIAGEN (300mg abacavir) and COMBIVIR (150/300mg lamivudine/zidovudine) in Subjects with HIV-1 ... (1 citation(s))
AZL30002	Phase 3	A Phase IIIb, Randomised, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of a Triple Combination Tablet (Trizivir) [abacavir, lamivudine, zidovudine] Versus Continued Antiretroviral Triple Therapy in HIV-1 Infected Subjects with Undetectable Plasma HIV-1 RNA Levels (TRIZAL) (4 citation(s))
AZL30004	Phase 3	A Phase IIIb/IV, Randomised, Open-Label, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of TRIZIVIR plus Efavirenz (Quad) Over 72 Weeks Versus Quad Therapy for 48 Weeks Followed by TRIZIVIR Alone for 24 Weeks Versus Quad Therapy for a minimum of 24 Weeks Followed by TRIZIVIR ... (3 citation(s))
AZL30004_1	Phase 3	A Phase IIIb/IV, Randomised, Open-Label, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability ofTRIZIVIR. plus Efavirenz (Quad) Over 72 Weeks Versus Quad Therapy for 48 Weeks Followed by TRIZIVIR Alone for24 Weeks Versus Quad Therapy for a minimum of 24 Weeks Followed by TRIZIVIR ... (3 citation(s))
AZL30006	Phase 3	See Detailed Description (0 citation(s))
AZL40001	Phase 4	An open-label, single arm, multicentre, pilot phase IV study to evaluate the efficacy and safety of a potent combination therapy (Trizivir + Efavirenz) in antiretroviral nave adults with a CD4+ cell count &lt;200mm3 over a 48-week treatment period (TETRA Trizivir Efavirenz TReAtment) (2 citation(s))
AZLF3002	Phase 3	Multicentre, open-label, pilot study to evaluate the efficacy and safety of a triple therapy combining AZT/3TC/ABC as a combined tablet of Trizivir, in HIV-infected patients with an undetectable viral load after quadruple therapy (COM, ABC, EFV) during CNAF 3008 study (La Francilienne). (0 citation(s))
AZLF3004	Phase 3	An Open-label study to evaluate long-term (48 weeks) safety and efficacy of switch to TRIZIVIR after first line quadruple induction therapy: AZLF3004-Trisud (1 citation(s))
CNAF3016	Phase 3	A Pilot Study to assess the Efficacy and Safety of a quadritherapy with Combivir, Abacavir, Nelfinavir switching from week 16 to (TZV), Nelfinavir for Antiretroviral Therapy in HIV-infected Naive Subjects with a viral load &gt; 50 000 copies/mL (0 citation(s))
COL30281	Phase 3	An open label, randomised study, to evaluate the safety and efficacy of Combivir plus abacavir (Ziagen) versus Combivir plus Viracept, in HIV-1 infected antiretroviral therapy naive adults with a plasma HIV-1 RNA between 1000 and 500,000 copies /mL. (1 citation(s))
COL30336	Phase 4	A Phase IV, Open-Label, Multicenter Study of the Efficacy and Safety of Quadruple Combination Antiretroviral Therapy with COMBIVIR (Lamivudine 150mg/Zidovudine 300mg) BID, ZIAGEN (Abacavir) 300mg BID, and SUSTIVA (Efavirenz) 600mg QD for 24 Weeks, Followed by Therapy with the Triple Nucleoside C ... (3 citation(s))
COL30441	Phase 3	A Pilot, Multicentre Study to Evaluate the Efficacy and Safety of an Antiretroviral Therapy with Trizivir [abacavir, lamivudine, zidovudine] and Efavirenz after a 14-week Structured Antiretroviral Treatment Interruption, in HIV-1 Infected Subjects with a Viral Load &gt; 5000 copies/mL… (2 citation(s))
COL30470	Phase 4	A Pilot, Randomised, Open-Label, Monocenter Study to Evaluate the Safety and Efficacy of a Quadruple Combination Therapy of Triple Combination Tablet (Trizivir) [abacavir, lamivudine, zidovudine] Plus Saquinavir-SGC/Ritonavir Versus Triple Combination Therapy of Combivir Plus Saquinavir-SGC/Rito ... (1 citation(s))
COL30494	Phase 4	An Open-Label Multicentre Study to Evaluate the Adherence to, General Satisfaction and Quality of Life After 24 Weeks Therapy With a Triple Combination tablet (TRIZIVIR™) [Abacavir, Lamivudine, and Zidovudine] in HIV-1 Infected Subjects With Undetectable Plasma HIV-1 RNA Levels (2 citation(s))
COL30528	Phase 3	An open label study to evaluate long term (96 weeks) safety and efficacy of switch to TRIZIVIR after first line quadruple induction therapy: AZLF 3006 – Suburbs 2 (1 citation(s))
COL30574	Phase 3	A phase IIIB, non-comparative, single arm, open-label, multicenter study on antiviral efficacy and safety of the approach “Induction- Maintenance” in patients with HIV-1 infection naïve to antiretroviral therapy. A 72-week study on the scheme: induction with TRIZIVIR® + SUSTIVA® or COMBIVIR® + SUSTIVA® OR COM (0 citation(s))
COL40263	Phase 3	A Pilot, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of a Once-Daily Regimen of Trizivir in Combination with Tenofovir Disoproxil Fumarate in Antiretroviral Therapy-Naïve Subjects with Viral Loads ?30,000 copies/mL (5 citation(s))
ESS 30005	Phase 4	A phase IV, open-label, multicenter study of treatment with TRIZIVIR (abacavir 300mg/lamivudine 150mg/zidovudine 300mg) twice daily and tenofovir 300mg once-daily for 48 weeks in HIV-infected subjects experiencing early virologic failure (ZIAGEN Intensification Protocol) (2 citation(s))
ESS40005	Phase 3	A Phase IIIB Randomized, Multi-center Study of the Efficacy and Safety of COMBIVIR 1 Tablet PO BID Plus ZIAGEN 300mg PO BID Versus an Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg Combination Tablet PO BID, Administered for 24 Weeks in Subjects With HIV-1 Infection (2 citation(s))
ESS40013	Phase 4	A Phase IV Multi-center Study of the Efficacy and Safety of 48-Week Induction Treatment with TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg Combination Tablet BID) + Efavirenz (600mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment with TRIZIVIR… (2 citation(s))
NZTA4006	Phase 3	A Phase IIIB, Open-Label, Randomized Study of the Effect of an Education Intervention on Virologic Outcomes, Adherence, Immunologic Outcome, and Health Outcomes in HIV-Infected Subjects from Under-Represented Populations Treated with Triple Nucleoside Therapy (COMBIVIR, Lamivudine 150mg/Zidovudi ... (1 citation(s))
WE066_EPI40007_1	N/A	The Antiretroviral Pregnancy Registry (APR, Registry) (1 citation(s))

Result Summaries: abacavir/lamivudine/zidovudine

Filter list by: